Skip to main content

Advertisement

SpringerLink
Log in

Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study

  • PHASE I STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Background Regional chemotherapy is used successfully in the treatment of both primary and secondary malignancies, in particular of the peritoneal surface and the liver, and is currently explored as an attractive approach for patients with locally advanced pancreatic ductal adenocarcinoma. To establish the feasibility and toxicity of regional intra-arterial gemcitabine delivered as a 24-h continuous infusion to the pancreas as a novel treatment option for patients with locally advanced PDAC a phase I clinical trial was conducted. Methods Between April 2011 and September 2013 six patients with biopsy confirmed, borderline or unresectable pancreatic adenocarcinoma, and having received at least one line of systemic chemotherapy, underwent vascular redistribution of the inflow to the head of the pancreas by arterial coil embolization followed by perfusion catheter placement within the splenic artery. Patients were treated with increasing doses of gemcitabine administered by continuous splenic arterial infusion over 24 h with inter-patient and intra-patient dose escalation scheme. The primary endpoint was toxicity of the intra-arterial gemcitabine regimen and to establish the maximum tolerated dose. Results Catheter placement and gemcitabine infusion was successful in all patients enrolled to date (n = 6). Four out of six patients experienced catheter tip migration requiring replacement or revision. Patients received a median of four doses of 24-h gemcitabine infusion. Two patients developed grade 3 and 4 duodenal ischemia and upper gastrointestinal bleeding. Median overall survival was 15.3 months and median time to progression was 3 months. Three patients (50 %, n = 3/6) progressed systemically. Two patients had stable disease >4 months following treatment and underwent pancreaticoduodenectomy. Conclusions While technically feasible to treat locally advanced pancreatic ductal adenocarcinoma, prolonged regional pancreatic perfusion with gemcitabine following pancreatic arterial redistribution carries a high risk for gastrointestinal toxicity. Shorter infusion schedules with frequent on treatment evaluations should be considered for future clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Cancer Facts and Figures (2013) American Cancer Society, Atlanta, GA

  2. Sener SF, Fremgen A, Menck HR, Winchester DP (1999) Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 189(1):1–7

    Article  CAS  PubMed  Google Scholar 

  3. Niederhuber JE, Brennan MF, Menck HR (1995) The National Cancer Data Base report on pancreatic cancer. Cancer 76(9):1671–1677

    Article  CAS  PubMed  Google Scholar 

  4. Janes RH Jr, Niederhuber JE, Chmiel JS, Winchester DP, Ocwieja KC, Karnell JH, Clive RE, Menck HR (1996) National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg 223(3):261–272

    Article  PubMed Central  PubMed  Google Scholar 

  5. Evans DB, Erickson BA, Ritch P (2010) Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. Ann Surg Oncol 17(11):2803–2805. doi:10.1245/s10434-010-1285-8

    Article  PubMed  Google Scholar 

  6. Whatcott CJ, Posner RG, Von Hoff DD, Han H (2012) Desmoplasia and chemoresistance in pancreatic cancer. In: Grippo PJ, Munshi HG (eds) Pancreatic cancer and tumor microenvironment. Transworld Research Network, Trivandrum

    Google Scholar 

  7. Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ, Bahary N (2013) Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol 108(4):236–241. doi:10.1002/jso.23392

    Article  CAS  PubMed  Google Scholar 

  8. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol 26(21):3496–3502. doi:10.1200/JCO.2007.15.8634

    Article  CAS  Google Scholar 

  9. Liu F, Tang Y, Sun J, Yuan Z, Li S, Sheng J, Ren H, Hao J (2012) Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE 7(7):e40847

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, Oku T, Akiyama T, Kusakabe T, Miyanishi K, Niitsu Y (2000) A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer 89(2):303–313

    Article  CAS  PubMed  Google Scholar 

  11. Aigner KR, Gailhofer S (2005) Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer—a phase II study on 265 cases. Anticancer Res 25(6C):4407–4412

    PubMed  Google Scholar 

  12. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol 15(6):2403–2413

    CAS  Google Scholar 

  13. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol 21(18):3402–3408. doi:10.1200/JCO.2003.09.140

    Article  CAS  Google Scholar 

  14. Davis JL, Pandalai P, Ripley RT, Langan RC, Steinberg SM, Walker M, Toomey MA, Levy E, Avital I (2011) Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial. Trials 12:129. doi:10.1186/1745-6215-12-129

    Article  PubMed Central  PubMed  Google Scholar 

  15. Shamseddine AI, Khalifeh MJ, Mourad FH, Chehal AA, Al-Kutoubi A, Abbas J, Habbal MZ, Malaeb LA, Bikhazi AB (2005) Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. Clin Pharmacokinet 44(9):957–967. doi:10.2165/00003088-200544090-00005

    Article  CAS  PubMed  Google Scholar 

  16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

    Article  CAS  PubMed  Google Scholar 

  17. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430

    Article  CAS  PubMed  Google Scholar 

  18. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, Asbun HJ, Bassi C, Buchler M, Charnley RM, Conlon K, Cruz LF, Dervenis C, Fingerhutt A, Friess H, Gouma DJ, Hartwig W, Lillemoe KD, Montorsi M, Neoptolemos JP, Shrikhande SV, Takaori K, Traverso W, Vashist YK, Vollmer C, Yeo CJ, Izbicki JR, International Study Group of Pancreatic S (2014) Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155(6):977–988. doi:10.1016/j.surg.2014.02.001

    Article  PubMed  Google Scholar 

  19. Shapiro N, Brandt L, Sprayregan S, Mitsudo S, Glotzer P (1981) Duodenal infarction after therapeutic Gelfoam embolization of a bleeding duodenal ulcer. Gastroenterology 80(1):176–180

    CAS  PubMed  Google Scholar 

  20. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50(14):4417–4422

    CAS  PubMed  Google Scholar 

  21. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51(22):6110–6117

    CAS  PubMed  Google Scholar 

  22. Veltkamp SA, Beijnen JH, Schellens JHM (2008) Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist 13(3):261–276. doi:10.1634/theoncologist.2007-0215

    Article  CAS  PubMed  Google Scholar 

  23. Anderson H, Thatcher N, Walling J, Hansen H (1996) A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 74(3):460–462

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Pollera CF, Ceribelli A, Crecco M, Oliva C, Calabresi F (1997) Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels. Investig New Drugs 15(2):115–121

    Article  CAS  Google Scholar 

  25. Rizzieri DA, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM, Petros WP, Adams DJ, Laughlin MJ, Davis P, Foster T, Jacobson R, Hurwitz H, Moore JO (2002) Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol Off J Am Soc Clin Oncol 20(3):674–679

    Article  CAS  Google Scholar 

  26. Gandhi V, Plunkett W, Du M, Ayres M, Estey EH (2002) Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol Off J Am Soc Clin Oncol 20(3):665–673

    Article  CAS  Google Scholar 

  27. Ji Z, Wang Y, Chen X, Wu T (2003) Peripancreatic artery ligation and artery infusion chemotherapy for advanced pancreatic carcinoma. Chin Med J 116(1):89–92

    CAS  PubMed  Google Scholar 

  28. Liu HQ, Li Y, Huang RW, Huang XP (2008) Clinical observation of transarterial infusion chemotherapy of GP for treatment of advanced pancreatic carcinoma. J Basic Clin Oncol 21:479–481

    Google Scholar 

  29. Hong G, Zhou J, Luo J, Xu L, Chen Y, Jiang R (2007) A clinical study on continuous transarterial infusion chemotherapy and systemic venous chemotherapy with gemcitabine and 5-fluorouracil in treating patients with advanced pancreatic carcinoma. Chin German J Clin Oncol 6(5):457–460. doi:10.1007/s10330-007-0086-4

    Article  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Thoracic & GI Oncology Branch, National Cancer Institute, Hatfield Center, CCR – 4 West/5940 10 Center Drive, Bethesda, MD, 20892-0001, USA

    Joal D. Beane, Kayla F. Griffin, Prakash Pandalai, Tatiana Beresnev, Yvonne Shutack, Carole C. Webb & Udo Rudloff

  2. Department of Interventional Radiology, National Cancer Institute, Bethesda, MD, USA

    Elliot B. Levy, Bradford Wood & Nadine Abi-Jaoudeh

  3. Bon Secours Cancer Institute, Richmond, VA, USA

    Itzhak Avital

Authors
  1. Joal D. Beane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kayla F. Griffin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elliot B. Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prakash Pandalai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bradford Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nadine Abi-Jaoudeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tatiana Beresnev
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yvonne Shutack
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carole C. Webb
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Itzhak Avital
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Udo Rudloff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Udo Rudloff.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beane, J.D., Griffin, K.F., Levy, E.B. et al. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study. Invest New Drugs 33, 109–118 (2015). https://doi.org/10.1007/s10637-014-0157-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-014-0157-7

Keywords

Search

Navigation